Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma

Boon, Eline; van Boxtel, Wim; Buter, Jan; Baatenburg de Jong, Robert J; van Es, Robert J J; Bel, Miranda; Fiets, Edward; Oosting, S. F.; Slingerland, Marije; Hoeben, Ann

Published in:
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

DOI:
10.1002/hed.25035

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2017

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands

Eline Boon MD1 | Wim van Boxtel MD1 | Jan Buter MD, PhD2 | Robert J. Baatenburg de Jong MD, PhD3 | Robert J. J. van Es MD, PhD4 | Miranda Bel Bsc1 | Edward Fiets MD, PhD5 | Sjoukje F. Oosting MD, PhD6 | Marije Slingerland MD, PhD7 | Ann Hoeben MD, PhD8 | Margot E. T. Tessaelaar MD, PhD9 | Marianne A. Jonker PhD10 | Uta E. Flucke MD, PhD11 | Nationwide Network and Registry of Histopathology and Cytopathology (PALGA) Group | Winette T. A. van der Graaf MD, PhD1,12 | Carla M. L. van Herpen MD, PhD1

1 Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands
2 Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
3 Department of Otorhinolaryngology/Head and Neck Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands
4 Department of Head and Neck Surgical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
5 Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden, The Netherlands
6 Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
7 Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands
8 Department of Medical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands
9 Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
10 Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands
11 Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands
12 The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK

Correspondence
Carla van Herpen, Department of Medical Oncology, Radboud University Medical Center, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.
Email: Carla.vanHerpen@radboudumc.nl

Abstract

Background: Salivary duct carcinoma, an aggressive subtype of salivary gland cancer, is mostly androgen receptor-positive. Only limited data are available on androgen deprivation therapy (ADT).

Methods: Patients with advanced androgen receptor-positive salivary duct carcinoma treated with first-line ADT were retrospectively evaluated for clinical benefit (ie, partial response [PR] and stable disease, progression-free survival [PFS] and overall
1 | INTRODUCTION

Salivary gland cancers comprise a heterogeneous group of carcinomas. Salivary duct carcinoma is a very aggressive subtype of salivary gland cancer with a high risk of distant metastatic disease. The median overall survival (OS) is approximately 3 years after primary diagnosis.1–3 In case of distant metastatic disease, no standard treatment options are available and most of the treatments described in literature are based on small case series or case reports.

Most salivary duct carcinomas express the androgen receptor4; the percentage of androgen receptor positivity varies between 67% and 89%.5–7 Based on this androgen receptor expression, patients have been treated with androgen deprivation therapy (ADT), such as bicalutamide, an androgen receptor antagonist with a nonsteroidal structure, similar to the treatment with ADT for patients with prostate cancer. Due to the rarity of the disease, a clinical study has never been performed. In 2011, we reported on 10 patients with salivary duct carcinoma treated with ADT in a single center (Radboud University Medical Center), with a clinical benefit rate of approximately 50% and a median progression-free survival (PFS) of 12 months in patients with clinical benefit.8 The purposes of this retrospective study are to determine the efficacy of ADT in a nationwide group of patients with incurable locally advanced or metastatic androgen receptor-positive salivary duct carcinoma in terms of response, duration of response, and median OS. In addition, we aim to describe the outcome of a group of patients with incurable locally advanced or metastatic salivary duct carcinoma who received best supportive care during the same period.

2 | PATIENTS AND METHODS

This study was performed in accordance with institutional ethical guidelines. In a retrospective search by the Nationwide Network and Registry of Histopathology and Cytopathology (PALGA) in The Netherlands, we collected all patients diagnosed with salivary duct carcinoma in the time period 1990-2014.9 An experienced pathologist (U.F.) reviewed all pathology slides for central confirmation of the diagnosis. This enabled us to collect data of 177 patients with salivary duct carcinoma. In The Netherlands, treatment of patients with head and neck cancer is centralized in 8 head and neck cancer centers and 6 collaborating major hospitals. Clinical data of all these patients, including age, sex, primary tumor site, presenting symptoms, pathological report (all reviewed), pathological TNM classification, expression of androgen receptor, development of local or locoregional recurrence, or distant metastases, treatment, such as surgery, radiotherapy, or systemic treatment, response evaluation in case of systemic treatment, PFS, and OS, were obtained by reviewing medical records with permission of the treating physicians. By Dutch law, a review by a medical ethical committee was not needed due to the retrospective nature of these observations. Of all 177 patients, only the 86 patients with distant metastatic (n = 84) or incurable locally advanced salivary duct carcinoma (n = 2) were analyzed in further detail. Patients treated with ADT as first-line palliative treatment were included for analysis about efficacy. Patients who received any other systemic treatment before ADT were excluded (chemotherapy, targeted therapy, or adjuvant systemic therapy before ADT). Ten patients of the current series were already described in an earlier report.9

2.1 | Androgen receptor testing

For all 177 patients with salivary duct carcinoma, efforts were made to evaluate the androgen receptor. In 140 patients, the androgen receptor was determined using the androgen receptor polyclonal antibody of Santa Cruz, dilution 1:200, pretreatment with citrate (pH 6.0) for 10 minutes in a PT...
module. Immunostaining was carried out with the Powervision method by Immunologic. The androgen receptor was scored positive or negative based on diffuse nuclear staining, as described in the World Health Organization classification of salivary duct carcinoma. For the remaining patients, no tumor material was available for additional androgen receptor staining. Therefore, the results of androgen receptor determined during routine clinical care procedures were used.

2.2 Treatment protocol

Patients who received ADT were treated with 150 mg bicalutamide once daily (q.d.) or a combination of a luteinizing hormone-releasing hormone (LHRH) analog (ie, goserelin 3.6 mg subcutaneously every 4 weeks, with 50 mg bicalutamide q.d.).

2.3 Response evaluation

Patients were evaluated approximately every 3 months. Tumor evaluation was measured using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Clinical benefit was defined as: complete response (CR), partial response (PR), or stable disease. The PFS was defined as the time between the start of ADT until the documented date of progressive disease (PD) or death, whatever came first. The OS was counted from the date of confirmation of distant metastasis until the date of death of any cause. Patients alive at last follow-up were included in the analysis as censored.

Clinical outcomes of ADT-treated patients were compared with clinical outcomes for patients with distant metastasis or incurable locally advanced disease who received best supportive care.

2.4 Statistical analysis

The OS was estimated by the Kaplan-Meier survival curves. The log-rank test was used to compare OS between different groups of patients. A $P$ value of $<.05$ was considered significant.

To study the association between treatment and survival, an association Cox regression model was fitted to the data. First, the regression model with only treatment as the independent variable was estimated. The hazard ratio in this model represents the association that is uncorrected for possible confounders (age, sex, androgen receptor status, primarily metastasized disease, and organ involvement). Next, the model was adjusted for possible confounders by a forward selection procedure. In every step, it was checked whether one of the possible confounders needed to be added to the model as an independent variable additional to the variables already included in the model. By including it into the model, the variable that causes the biggest change in the association between treatment and survival (estimate of the regression coefficient) but at least 10% and had a $P$ value of, at the most, 10% (Wald-test), was selected for inclusion to the model. Analyses were performed using SPSS version 22.0.

3 RESULTS

3.1 Patient selection

A total of 177 patients with salivary duct carcinoma were retrieved from the nationwide search. Eighty-six patients had incurable locally advanced ($n = 2$) or metastatic ($n = 84$) salivary duct carcinoma, of which 38 were treated with ADT. Of these 38 patients, 3 patients were excluded: 2 patients because they received chemotherapy as first-line treatment before ADT, and another patient because of prior adjuvant ADT. Forty-four patients received best supportive care, of which 1 patient was excluded because this patient received adjuvant ADT, which led to a total of 43 patients who received best supportive care only. The other 4 patients received chemotherapy and/or targeted therapy only and were not included in the analysis. Figure 1 shows the flow chart of these patients.

3.2 Patient characteristics and treatment

The baseline characteristics of the 35 patients receiving first-line ADT and the 43 patients receiving best supportive care are displayed in Table 1. Patients were median 64 and 68 years of age, and 86% and 81% of the patients were men, respectively. The percentage of the sites of distant metastases and the number of sites of distant metastases per patient are shown in Table 1.

Androgen receptor status was determined using the polyclonal androgen receptor antibody from Santa Cruz in 17 of 35 ADT-treated patients and 33 of 43 best supportive care-treated patients. For the remaining patients, no tumor material was available for additional androgen receptor staining. Therefore, the results of androgen receptor as determined during routine clinical care were used. In 6 best supportive care-treated patients, the androgen receptor expression was not determined and, therefore, unknown.

Of the ADT-treated patients, 28 patients (80%) received single-agent bicalutamide, whereas 7 patients (20%) received an LHRH analog in combination with low-dose bicalutamide.

Although ADT was usually well tolerated, 1 patient switched to another form of ADT and 2 male patients (6%) stopped because of presumed toxicity (ie, fatigue and loss of appetite).

3.3 Response to androgen deprivation therapy and survival

Of the 35 ADT-treated patients, 1 patient requested to discontinue treatment before the first evaluation and was left
out of the response evaluations. Six of 34 evaluable patients (18%) had a PR, 11 (32%) had stable disease, and 17 (50%) had PD (Table 2). All patients with a PR were treated with bicalutamide monotherapy. Figure 2 shows the CT imaging at baseline and after 15 months of ADT in a patient with PR. In total, 50% had clinical benefit and stayed on treatment for a median duration of 11 months (95% confidence interval [CI] 6-15 months). Median PFS for all ADT-treated patients was 4 months (95% CI 3-5 months; Table 2). At the time of analysis, 6 patients were still on first-line ADT.

The median follow-up time was 10 months (range 1-64 months). The median OS for ADT-treated patients was 17 months (95% CI 10-24 months). The median OS for the ADT-treated patients with clinical benefit was 29 months (95% CI 8-51 months) and for patients with PD this was 8 months (95% CI 5-10 months; Table 2). Two of 5 female patients had a PR on ADT. Possibly because the numbers are small, we did not observe significant differences in OS or PFS between male and female patients treated with ADT, nor did we observe a significant difference between patients treated with single-agent bicalutamide or LHRH analogs with bicalutamide.

The median OS for patients treated with best supportive care was 5 months (95% CI 1-9 months; Table 2). The association between treatment and survival was investigated by means of estimating a Cox regression model. No confounders were found. The estimated survival curve for ADT-treated patients in a Cox regression model is shown in Figure 3. The ADT-treated patients had a significantly better OS than best supportive care patients in this Cox regression model ($P = .024$; hazard ratio 0.53; 95% CI 0.30-0.92).

### 3.4 Consecutive systemic treatments

After PD on ADT as first-line treatment, 11 patients received second-line ADT. Depending on the agents the patients received as first line, patients were treated with an LHRH analog, either as monotherapy, or combined with bicalutamide and/or a 5-alfa-reductase-inhibitor. Of the 10 patients treated...
with first-line bicalutamide monotherapy, 2 patients were consecutively treated with an LHRH analog, 7 patients with an LHRH analog in combination with low-dose bicalutamide (50 mg), and 1 patient with a combination of an LHRH analog, bicalutamide, and 5-alpha-reductase-inhibitor. One patient treated with an LHRH analog in combination with low-dose bicalutamide in first-line, was treated in second-line with an LHRH analog.

Six patients had stable disease for a median of 9 months (95% CI 6-12 months), 4 patients had PD, and 1 patient did not have the first evaluation yet. The 6 patients with stable disease on second-line ADT previously had stable disease (4 patients) or PD (2 patients) on first-line ADT. One patient received third-line ADT and had stable disease for another 7 months, after also having stable disease, on first-line and second-line ADT.

Ten patients received chemotherapy as second-line or third-line treatment after first-line ADT; 2 of those patients received anti-human epidermal growth factor receptor 2 (HER2) therapy in combination with docetaxel; 1 patient was treated only with trastuzumab, and the other patient was treated with a combination of trastuzumab and pertuzumab. Five patients had a PR, 3 patients had stable disease and 2 patients had PD.

### 4 | DISCUSSION

Salivary duct carcinoma is a rare and aggressive subtype of salivary gland cancer. Results on ADT in androgen receptor-positive incurable locally advanced or metastatic salivary duct carcinomas are scarce. We aimed to collect data of patients with salivary duct carcinoma over a period of 25 years in The Netherlands. In this way, we were able to describe the largest retrospective series of patients with salivary duct carcinoma treated with ADT so far and describe a

### TABLE 1 Baseline characteristics of patients with incurable locally advanced or metastatic salivary duct carcinomas

<table>
<thead>
<tr>
<th></th>
<th>ADT No. of patients = 35</th>
<th>BSC No. of patients = 43</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median age, years, range</td>
<td>64 (38-83)</td>
<td>68 (42-84)</td>
</tr>
<tr>
<td>Sex, no. of patients (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>30 (86)</td>
<td>35 (81)</td>
</tr>
<tr>
<td>Female</td>
<td>5 (14)</td>
<td>8 (19)</td>
</tr>
<tr>
<td>Androgen receptor expression, no. of patients (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>35 (100)</td>
<td>35 (81)</td>
</tr>
<tr>
<td>Negative</td>
<td>0</td>
<td>2 (5)</td>
</tr>
<tr>
<td>Not performed</td>
<td>0</td>
<td>6 (17)</td>
</tr>
<tr>
<td>Distant metastasis, no. of patients (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Presenting with distant metastases</td>
<td>10 (29)</td>
<td>1 (2)</td>
</tr>
<tr>
<td>Sequential presentation of distant metastases</td>
<td>23 (66)</td>
<td>42 (98)</td>
</tr>
<tr>
<td>Median time between diagnosis and metastases, months (range)</td>
<td>15 (1-69)</td>
<td>14 (1-46)</td>
</tr>
<tr>
<td>Sites of distant metastasis, no. of patients (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lungs</td>
<td>20 (57)</td>
<td>19 (44)</td>
</tr>
<tr>
<td>Bones</td>
<td>19 (54)</td>
<td>16 (63)</td>
</tr>
<tr>
<td>Lymph nodes</td>
<td>22 (63)</td>
<td>8 (19)</td>
</tr>
<tr>
<td>Liver</td>
<td>7 (20)</td>
<td>12 (28)</td>
</tr>
<tr>
<td>Brain</td>
<td>3 (9)</td>
<td>8 (19)</td>
</tr>
<tr>
<td>Other</td>
<td>5 (14)</td>
<td>5 (12)</td>
</tr>
</tbody>
</table>

No. of involved organs per patient, no. of patients (%)

<table>
<thead>
<tr>
<th>Number of involved organs</th>
<th>ADT No. of patients = 35</th>
<th>BSC No. of patients = 43</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 involved organs</td>
<td>2 (6)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>1 involved organ</td>
<td>12 (34)</td>
<td>26 (61)</td>
</tr>
<tr>
<td>2 involved organs</td>
<td>6 (17)</td>
<td>11 (26)</td>
</tr>
<tr>
<td>3 involved organs</td>
<td>10 (29)</td>
<td>4 (9)</td>
</tr>
<tr>
<td>4 involved organs</td>
<td>3 (9)</td>
<td>2 (5)</td>
</tr>
<tr>
<td>5 involved organs</td>
<td>2 (6)</td>
<td>0 (0)</td>
</tr>
</tbody>
</table>

Abbreviation: ADT, androgen deprivation therapy; BSC, best supportive care.

Patients receiving ADT and best supportive care (BSC) are mentioned separately.

### TABLE 2 Response evaluation, progression-free survival, and overall survival of androgen deprivation therapy-treated patients

<table>
<thead>
<tr>
<th></th>
<th>ADT No. of patients = 35</th>
<th>BSC No. of patients = 43</th>
</tr>
</thead>
<tbody>
<tr>
<td>Response evaluation, no. of patients (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PR</td>
<td>6 (18)</td>
<td></td>
</tr>
<tr>
<td>Stable disease</td>
<td>11 (32)</td>
<td></td>
</tr>
<tr>
<td>PD</td>
<td>17 (50)</td>
<td></td>
</tr>
<tr>
<td>Not evaluable</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Median PFS in months [95% CI]</td>
<td>4 [3-5]</td>
<td></td>
</tr>
<tr>
<td>Median PFS in patients with PR or stable disease in months [95% CI]</td>
<td>11 [6-15]</td>
<td></td>
</tr>
<tr>
<td>Median OS in months [95% CI]</td>
<td>17 [10-24]</td>
<td>5 [1-9]</td>
</tr>
</tbody>
</table>

Abbreviations: ADT, androgen deprivation therapy; BSC, best supportive care; CI, confidence interval; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response.

The OS for best supportive care patients is also shown.

*There were 34 evaluable patients.
separate group of patients who received best supportive care during the same time period. In 35 patients treated with first-line ADT for salivary duct carcinoma, 18% had PR and 32% had stable disease, resulting in a clinical benefit rate of 50% with a median treatment duration of 11 months for patients with clinical benefit. The median PFS and OS of the ADT-treated patients were 4 months and 17 months, respectively. The OS of ADT-treated patients was significantly better than that of best supportive care patients. However, as not all patients responded to ADT, future research should focus on biomarkers that predict the response of patients to ADT and mechanisms of intrinsic and acquired resistance to ADT.\textsuperscript{12}

One may assume that female patients could have less benefit from ADT due to the lower physiological presence of androgen, and, thus, less stimulation of androgen receptor-positive tumor cells. However, 2 of 5 female patients had sustained PR and no differences in OS and PFS for male and female patients were found.

The incidence of adverse events of ADT-treated patients seemed to be low, although this may be due to underreporting in this retrospective case series. On the other hand, ADT is a commonly used therapy for patients with prostate cancer, with a well-known low toxicity profile.\textsuperscript{13}

Obviously, this study has some limitations. The first one is its retrospective design, which is largely due to the rarity of the disease. Performing studies in such rare cancer types is notoriously difficult and, with a central pathological review, we have done the best attempt as possible to collect data of a homogeneous group of patients with salivary duct carcinoma. Second, we compared OS in ADT-treated patients with best supportive care patients, which could suggest that bias played a role. Unfortunately, we could not retrieve the World Health Organization performance score of patients included in this analysis to investigate this issue. However, we did perform a Cox regression analysis on OS to adjust for possible confounders, measured at diagnosis of incurable locally advanced or metastatic disease. Age, sex, androgen receptor status, metastasized disease at diagnosis, and organ involvement were evaluated as possible confounders, but no confounders were found. Additionally, the majority of patients who received ADT were treated in 1 hospital (74%), because part of the hospitals may not have been familiar with ADT in patients with androgen receptor-positive salivary duct carcinoma, which pleads against selection bias.

Our objective response rate and clinical benefit rate on ADT in patients with androgen receptor-positive locally advanced or metastatic salivary duct carcinoma might be slightly lower than case series described in literature.
Locati et al. reported on 17 patients with androgen receptor-positive salivary gland cancer (ie, salivary duct carcinoma and also other adenocarcinomas) treated with ADT and found an overall response rate of 65%. Of the 8 patients with salivary duct carcinoma, 2 patients had CR, 2 patients had PR, and 3 patients had stable disease. Furthermore, Yajima et al. reported on 8 patients with salivary duct carcinoma, with 2 patients with PR and 3 patients with stable disease.

In addition to ADT, other therapies may be considered. In a retrospective series of 18 patients with salivary duct carcinoma treated with carboplatin and paclitaxel, they had a median PFS of 6.5 months and median OS of 34.7 months. In case of HER2-positive salivary duct carcinoma, which is observed in 21%-44% of patients with salivary duct carcinoma, trastuzumab may be added to chemotherapy. In fact, trastuzumab-based treatment regimens have shown some promising responses. In 2 separate reports, a total of 8 patients were treated with paclitaxel, carboplatin, and trastuzumab. Two patients had CR (duration 36 and 52 months) and 2 patients had PR (duration 20 and 36 months).

Basket studies may offer a promising way to investigate new treatment options for patients with salivary duct carcinoma. Based on our results and literature, we suggest as first-line treatment ADT in androgen receptor-positive salivary duct carcinoma due to efficacy and tolerability. The choice of bicalutamide monotherapy or LHRH analogue with low-dose bicalutamide depends on patient characteristics, such as age and sex. Multiple lines of ADT may be given before considering chemotherapy. In patients with a more aggressive course of the disease, chemotherapy may be considered. In HER2-positive salivary duct carcinoma, trastuzumab and pertuzumab may be added to chemotherapy. One of the patients treated with docetaxel, pertuzumab, and trastuzumab after ADT was discussed in a separate paper. Finally, patients can be analyzed for targetable mutations and treated accordingly.

For future research, combining chemotherapy with ADT in androgen receptor-positive salivary duct carcinoma may be interesting as an analog to recent insights in prostate cancer (CHAARTED trial). In this randomized trial, first-line ADT was compared to docetaxel plus ADT and showed a significant OS benefit for the latter.

A randomized phase II European Organisation for Research and Treatment of Cancer trial (clinical trial number NCT01969578) is currently including patients with androgen receptor-positive recurrent or metastatic salivary gland carcinomas. Patients are randomized between chemotherapy (either cisplatin with doxorubicin or carboplatin with paclitaxel) and ADT (triptorelin and bicalutamide). The results of this trial will probably give more insight in treatment for androgen receptor-positive salivary gland cancer.

One may wonder, with the aggressive behavior of salivary duct carcinoma, and the shown efficacy of ADT in the metastatic setting, if adjuvant treatment with ADT is necessary. If the disease is not responsive to chemotherapy, other treatment modalities should be considered, such as surgery, radiation therapy, or targeted therapy. However, the exact role of these treatments in the management of salivary duct carcinoma is still under investigation.

### TABLE 3
Overview of studies on treatment with androgen deprivation therapy for patients with androgen receptor-positive salivary duct carcinoma

<table>
<thead>
<tr>
<th>Author</th>
<th>No. of patients</th>
<th>ADT</th>
<th>CR (%)</th>
<th>PR (%)</th>
<th>Stable disease (%)</th>
<th>PD (%)</th>
<th>Clinical benefit, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current paper†</td>
<td>35b</td>
<td>Bicalutamide +/- LHRH analogue</td>
<td>0</td>
<td>6 (18)</td>
<td>11 (32)</td>
<td>17 (50)</td>
<td>50</td>
</tr>
<tr>
<td>Jaspers et al8</td>
<td>10</td>
<td>Bicalutamide +/- LHRH analogue</td>
<td>0</td>
<td>2 (20)</td>
<td>3 (30)</td>
<td>5 (50)</td>
<td>50</td>
</tr>
<tr>
<td>Locati et al14</td>
<td>8</td>
<td>Bicalutamide or cyproterone acetate (1 patient) + LHRH analogue</td>
<td>2 (25)</td>
<td>2 (25)</td>
<td>3 (38)</td>
<td>1 (13)</td>
<td>87</td>
</tr>
<tr>
<td>Yajima et al15</td>
<td>8</td>
<td>LHRH analogue</td>
<td>0</td>
<td>2 (25)</td>
<td>3 (38)</td>
<td>3 (38)</td>
<td>63</td>
</tr>
</tbody>
</table>

Abbreviations: ADT, androgen deprivation therapy; CR, complete response; LHRH, luteinizing hormone-releasing hormone; PD, progressive disease; PR, partial response.

† Ten patients described in the current article were published before.8
b There were 34 evaluable patients.
Clinical benefit is CR + PR + stable disease.
warranted. The benefit of adjuvant ADT will, however, be difficult to demonstrate.

In conclusion, treatment with ADT in androgen receptor-positive salivary duct carcinoma can be recommended given its response, clinical benefit, and median OS benefit as compared with patients treated with best supportive care. Further research to select patients with androgen receptor-positive salivary duct carcinoma who are most likely to benefit from ADT is warranted.

ACKNOWLEDGMENTS
We thank M.H. Liedenbaum for providing the radiology images in this article. We also thank all the pathologists and clinicians for their contribution to patient selection and inclusion. Pathologist, Affiliation: J. Meijer, Rijnstate, Arnhem, The Netherlands; J.E. van der Wal: Martini, Groningen, The Netherlands; L. Arensman, Meander MC, Amersfoort, The Netherlands; S.M. Willems, University Medical Center Utrecht, Utrecht, The Netherlands; E. Bloemen, VU University Medical Center, Amsterdam, The Netherlands; L.A. Smit, Netherlands Cancer Institute, Amsterdam, The Netherlands; the Tissue Bank, University Medical Center Groningen, and the Stichting Laboratorium Pathologie Oost-Nederland, The Netherlands.

ORCID
Eline Boon MD https://orcid.org/0000-0002-9768-2911
Wim van Boxtel MD https://orcid.org/0000-0002-2724-1352

REFERENCES


